{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:03:53Z","timestamp":1785542633693,"version":"3.56.0"},"reference-count":56,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:00:00Z","timestamp":1734825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>This review will discuss heart failure, introduce a new drug finerenone, and discuss clinical studies with a focus on its effects on heart failure. Heart failure is a condition or syndrome characterized by an impairment of the pumping ability of the heart, thus no longer keeping up with the demands of the body. There are several types of heart failure; among them are heart failure with reduced ejection fraction, with mildly reduced ejection fraction and with preserved ejection fraction. Heart failure can be caused by several factors including lifestyle factors and diseases such as hypertension, type 2 diabetes mellitus and other cardiovascular diseases. Chronic kidney disease is also a risk factor of heart failure, as it leads to a state of inflammation that can impair the cardiovascular system over time. The novel nonsteroidal mineralocorticoid receptor antagonist finerenone antagonizes the mineralocorticoid receptor and thereby decreases the amount of fibrosis and inflammation that is observed in many heart failure patients. It shows an equal tissue distribution among heart and kidney, a high affinity and selectivity for the mineralocorticoid receptor and little risk of hyperkalemia and feminization. It also exhibits a reduction in the incidence of cardiovascular outcomes among patients with chronic kidney disease and type 2 diabetes mellitus. Therefore, finerenone has been proposed as a beneficial medication for reducing heart failure, especially in patients with diabetes and chronic kidney disease. Further studies are to be conducted to clarify the effects of finerenone alone and in combination with other drugs.<\/jats:p>","DOI":"10.3390\/ijms252413711","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T04:33:29Z","timestamp":1734928409000},"page":"13711","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Finerenone in Heart Failure\u2014A Novel Therapeutic Approach"],"prefix":"10.3390","volume":"25","author":[{"given":"Amalie","family":"Holst-Hansen","sequence":"first","affiliation":[{"name":"Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4991-3105","authenticated-orcid":false,"given":"Daniela","family":"Grimm","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark"},{"name":"Department of Microgravity and Translational Regenerative Medicine, Otto von Guericke University, 39106 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8160-859X","authenticated-orcid":false,"given":"Markus","family":"Wehland","sequence":"additional","affiliation":[{"name":"Department of Microgravity and Translational Regenerative Medicine, Otto von Guericke University, 39106 Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_2","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2337\/cd21-0050","article-title":"Finerenone","volume":"39","author":"Marcath","year":"2021","journal-title":"Clin. Diabetes"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone Reduces Risk of Incident Heart Failure in Patients with Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"ref_6","unstructured":"Heart.org (2024, December 19). Types of Heart Failure. Available online: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/what-is-heart-failure\/types-of-heart-failure."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1161\/01.CIR.49.1.152","article-title":"Experimental pulmonary embolism; effect on pulmonary blood volume and vascular compliance","volume":"49","author":"Alpert","year":"1974","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.15420\/cfr.2019.15.2","article-title":"Right Ventricular Failure: Pathophysiology, Diagnosis and Treatment","volume":"5","author":"Arrigo","year":"2019","journal-title":"Card. Fail. Rev."},{"key":"ref_10","unstructured":"Heart.org (2024, December 19). Classes and Stages of Heart Failure. Available online: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/what-is-heart-failure\/classes-of-heart-failure."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.37765\/ajmc.2022.89272","article-title":"Rethinking heart failure: Patient classification and treatment","volume":"28","author":"Clark","year":"2022","journal-title":"Am. J. Manag. Care"},{"key":"ref_12","unstructured":"Heart.org (2024, December 19). Risks for Heart Failure. Available online: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/causes-and-risks-for-heart-failure."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10741-020-09987-z","article-title":"Pathogenesis of chronic heart failure: Cardiovascular aging, risk factors, comorbidities, and disease modifiers","volume":"27","author":"Triposkiadis","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"ref_14","unstructured":"Heart.org (2024, December 19). What Causes Heart Failure?. Available online: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/causes-and-risks-for-heart-failure\/causes-of-heart-failure."},{"key":"ref_15","unstructured":"Heart.org (2024, December 19). Heart Failure Signs And Symptoms. Available online: https:\/\/www.heart.org\/en\/health-topics\/heart-failure\/warning-signs-of-heart-failure."},{"key":"ref_16","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pop.2023.08.004","article-title":"An Update on Heart Failure: New Definitions and Treatment","volume":"51","author":"Fragin","year":"2024","journal-title":"Prim. Care"},{"key":"ref_19","unstructured":"(2024, December 19). Compound Summary Finerenone, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/60150535."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.kisu.2021.11.001","article-title":"Mineralocorticoid receptor activation and antagonism in cardiovascular disease: Cellular and molecular mechanisms","volume":"12","author":"Bauersachs","year":"2022","journal-title":"Kidney Int. Suppl."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Di Lullo, L., Lavalle, C., Scatena, A., Mariani, M.V., Ronco, C., and Bellasi, A. (2023). Finerenone: Questions and Answers-The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist. J. Clin. Med., 12.","DOI":"10.3390\/jcm12123992"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: The FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cardfail.2024.04.015","article-title":"Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults with Heart Failure","volume":"30","author":"Ostrominski","year":"2024","journal-title":"J. Card. Fail."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chimura, M., Wang, X., Jhund, P.S., Henderson, A.D., Claggett, B.L., Desai, A.S., Fonseca, C., Goncalvesova, E., Katova, T., and Mueller, K. (2024). Finerenone in Women and Men with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol., e244613.","DOI":"10.1001\/jamacardio.2024.4613"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood Pressure and Cardiorenal Outcomes with Finerenone in Chronic Kidney Disease in Type 2 Diabetes","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2337\/dc21-1944","article-title":"Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","article-title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes","volume":"41","author":"Agarwal","year":"2023","journal-title":"J. Hypertens."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10741-019-09829-7","article-title":"New perspectives and future directions in the treatment of heart failure","volume":"25","author":"Pellicori","year":"2020","journal-title":"Heart Fail. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","article-title":"Rationale and design of ARTS: A randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease","volume":"14","author":"Pitt","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","article-title":"Finerenone and Heart Failure Outcomes by Kidney Function\/Albuminuria in Chronic Kidney Disease and Diabetes","volume":"10","author":"Filippatos","year":"2022","journal-title":"JACC Heart Fail."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/dom.14999","article-title":"Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline","volume":"25","author":"McGill","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2215\/CJN.0000000000000149","article-title":"Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis","volume":"18","author":"Sarafidis","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_42","unstructured":"European-Medicines-Agency (2024, September 23). Kerendia, INN-Finerenone. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kerendia-epar-product-information_en.pdf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ejhf.218","article-title":"Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): A randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and\/or chronic kidney disease","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"ref_44","first-page":"e21314","article-title":"Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells","volume":"35","author":"Perrot","year":"2021","journal-title":"FASEB J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone Reduces New-Onset Atrial Fibrillation in Patients with Chronic Kidney Disease and Type 2 Diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"102742","DOI":"10.1016\/j.cpcardiol.2024.102742","article-title":"Effects of mineralocorticoid receptor antagonists on new-onset or recurrent atrial fibrillation: A Bayesian and frequentist network meta-analysis of randomized trials","volume":"49","author":"Karakasis","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_47","unstructured":"Clinicaltrials.gov (2024, September 23). A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF) (CONFIRMATION), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06024746?cond=%22Heart%20failure%22&intr=Finerenone&page=1&rank=3."},{"key":"ref_48","unstructured":"Clinicaltrials.gov (2024, September 23). Polypill for Prevention of Cardiomyopathy (PolyPreventHF), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06143566?cond=%22Heart%20failure%22&intr=Finerenone&page=2&rank=12."},{"key":"ref_49","unstructured":"Clinicaltrials.gov (2024, September 23). Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes (Steno1), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06082063?cond=%22Heart%20failure%22&intr=Finerenone&page=2&rank=13."},{"key":"ref_50","unstructured":"Clinicaltrials.gov (2024, September 23). Efficacy and Safety of Finerenone in Heart Failure with Reduced Ejection Fraction, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05974566?cond=%22Heart%20failure%22&intr=Finerenone&page=2&rank=14#collaborators-and-investigators."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/dom.13393","article-title":"Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction","volume":"20","author":"Lachaux","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Gonzalez-Blazquez, R., Somoza, B., Gil-Ortega, M., Martin Ramos, M., Ramiro-Cortijo, D., Vega-Martin, E., Schulz, A., Ruilope, L.M., Kolkhof, P., and Kreutz, R. (2018). Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01131"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Vaduganathan, M., Claggett, B.L., Desai, A.S., Jhund, P.S., Lam, C.S.P., Senni, M., Shah, S.J., Voors, A.A., Zannad, F., and Pitt, B. (2024). Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol., e243782.","DOI":"10.1001\/jamacardio.2024.3782"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"102615","DOI":"10.1016\/j.cpcardiol.2024.102615","article-title":"Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: A systematic review and network meta-analysis of 32 randomized trials","volume":"49","author":"Pamporis","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12933-022-01676-5","article-title":"Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"21","author":"Zhang","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e1230","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/24\/13711\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:57:56Z","timestamp":1760115476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/24\/13711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,22]]},"references-count":56,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["ijms252413711"],"URL":"https:\/\/doi.org\/10.3390\/ijms252413711","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,22]]}}}